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of neuronal targets, are ineffective in a third of patients with
epilepsy, and do not show disease-modifying properties.
MicroRNAs are small noncoding RNAs that regulate levels of
proteins by post-transcriptional control of mRNA stability
and translation. MicroRNA-134 is involved in controlling
neuronal microstructure and brain excitability and previous
studies showed that intracerebroventricular injections of
locked nucleic acid (LNA), cholesterol-tagged antagomirs
targeting microRNA-134 (Ant-134) reduced evoked and spon-
taneous seizures in mouse models of status epilepticus. Trans-
lation of these ﬁndings would beneﬁt from evidence of efﬁcacy
in non-status epilepticus models and validation in another spe-
cies. Here, we report that electrographic seizures and convul-
sive behavior are strongly reduced in adult mice pre-treated
with Ant-134 in the pentylenetetrazol model. Pre-treatment
with Ant-134 did not affect the severity of status epilepticus
induced by perforant pathway stimulation in adult rats, a
toxin-free model of acquired epilepsy. Nevertheless, Ant-134
post-treatment reduced the number of rats developing sponta-
neous seizures by 86% in the perforant pathway stimulation
model and Ant-134 delayed epileptiform activity in a rat
ex vivo hippocampal slice model. The potent anticonvulsant ef-
fects of Ant-134 in multiple models may encourage pre-clinical
development of this approach to epilepsy therapy.Received 24 June 2016; accepted 29 November 2016;
http://dx.doi.org/10.1016/j.omtn.2016.11.002.
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Epilepsy is a common and serious chronic neurological disease that
affects over 50 million people worldwide. Anti-epileptic drugs
(AEDs) are effective at controlling seizures in many patients, acting
through a range of neuronal targets, including ion channels, neuro-
transmitter release, and receptor mechanisms.1,2 However, a thirdMolecula
This is an open access article under the CC BY-Nof patients with epilepsy fail to achieve seizure freedom, and current
AEDs do not show disease-modifying properties. Future treatments
for epilepsy need to differentiate from currently marketed drugs,
for example, by having a novel mechanism(s) of action or providing
disease-modifying effects.1,2
Acquired epilepsy is thought to result from disturbances to the
expression and function of neurotransmitters and their receptors,
ion channels, and signaling components, as well as altered meta-
bolism, neuronal and glial microstructure, neuroinﬂammation, and
other mechanisms.3–5 It is likely that disease-modifying treatments
will need to inﬂuence multiple genes within a given pathway or in
various independent pathways. Potential gene network control points
were recently identiﬁed and includemaster regulators of transcription
and neuroinﬂammation,6 epigenetic factors,7 and noncoding RNAs.8
MicroRNAs (miRNAs) are a conserved family of endogenous small
noncoding RNAs that regulate protein levels in cells by post-tran-
scriptional control of mRNA stability and translation.9,10 This is
achieved by sequence-speciﬁc binding of the miRNA to complemen-
tary bases in themRNA target.11 Since this generally requires only a 7-
to 8-nucleotide match, individual miRNAs can potentially target large
numbers of mRNAs.12 This provides the ability to regulate entire gene
networks or multiple biological processes and has been demonstrated
in the brain.13 MicroRNA-134 (miR-134) was identiﬁed as a brain-
enriched, neuronally expressed miRNA that controls dendrite spiner Therapy: Nucleic Acids Vol. 6 March 2017 ª 2016 The Author(s). 45
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Molecular Therapy: Nucleic Acidsmorphogenesis, via repression of LIM domain kinase 1 and other
targets.14,15 This is potentially important for disorders of hyperexcit-
ability, since dendritic spines are contact points for excitatory
communication and there is evidence that reorganization of dendrites
is a feature of experimental and human epilepsy.16,17 We identiﬁed
miR-134 among upregulated miRNAs proﬁled in areas of hippocam-
pal damage following status epilepticus induced by intra-amygdala
kainic acid (KA) in mice.18 Expression of miR-134 is also upregulated
after neuronal stimulation and seizures in various other in vitro and
in vivo models,15,19–22 and miR-134 is overexpressed in the resected
human neocortex from patients with intractable temporal lobe epi-
lepsy (TLE).19 Silencing miR-134 by intracerebroventricular (i.c.v.)
injection of locked nucleic acid (LNA), cholesterol-tagged antagomirs
(Ant-134) reduced levels of miR-134 for at least a month and
rendered mice refractory to the convulsant effects of both KA and
pilocarpine.19,22 Consistent with known miR-134 targets,14 LIM
domain kinase 1 and levels of other miR-134 targets were higher in
Ant-134-treated mice after status epilepticus and the dendritic spine
volume was increased.19,22 Notably, injection of Ant-134 after status
epilepticus suppressed the later occurrence of spontaneous recurrent
seizures in the intra-amygdala KA model in mice.19
There is signiﬁcant interest in developing miRNA-based thera-
pies.23,24 There are also barriers to antisense-based approaches and
there has been some disengagement of industry from pursuing such
efforts.25 This is likely to be a problem for any new therapy for epi-
lepsy, particularly one that is not based on traditional small molecule
chemistry.1,2 Pre-clinical development of an miR-134-based treat-
ment for epilepsy might be more attractive if additional important
questions are answered. Principally, work to date has only tested
Ant-134 in mouse models of status epilepticus. Proof of seizure-sup-
pressive effects of Ant-134 in a non-status epilepticus model or in
another species would bridge the gap in evidence and facilitate pre-
clinical development of Ant-134-based treatment for epilepsy.26,27
Here, we evaluated miR-134 expression in the resected hippocampus
from patients with pharmacoresistant TLE and we tested Ant-134 in
three different models. We used the pentylenetetrazol (PTZ) model in
mice, a popular method for screening putative anticonvulsive effects
that triggers seizures via g-amino butyric acid (GABA) blockade.26,28
Second, the perforant pathway stimulation (PPS) model, a toxin-free
model of acquired epilepsy based on nonconvulsive status epilepticus
that avoids the confounding inﬂuence of exposing the brain to che-
moconvulsants, was used in rats.29 Finally, we used a high-potassium
model of epileptiform activity,30 using ex vivo brain slices from rats
pre-treated with Ant-134. Our results establish that targeting miR-
134 offers broad anticonvulsant and possibly disease-modifying ef-
fects in experimental epilepsy, which may encourage pre-clinical
development of Ant-134 as a treatment for epilepsy.
RESULTS
miR-134 Levels in the Hippocampus from Patients with
Pharmacoresistant TLE
We ﬁrst sought to extend the clinical relevance of targeting miR-134
in epilepsy. For this, we analyzed levels of miR-134 in the surgically46 Molecular Therapy: Nucleic Acids Vol. 6 March 2017obtained hippocampus from adults with pharmacoresistant TLE
and we compared ﬁndings to autopsy hippocampal samples from
people who died of causes unrelated to neurological disease. These
samples were used previously to analyze expression of other genes,31
and clinical data for both groups are brieﬂy summarized in Tables S1
and S2. There were no between-group differences in patient age, and
each group included males and females. We detected higher levels
(p = 0.037) of mature miR-134 in the TLE specimens compared to au-
topsy samples (Figure 1A). This difference is unlikely to be an artifact
of post mortem delay, since miR-134 levels did not decrease in simu-
lated autopsy experiments lasting up to 12 hr.19
Increased miR-134 Levels after PTZ-Induced Seizures in Mice
We began by establishing dosing parameters in the mouse PTZ
model. Generalized tonic-clonic seizures were ﬁrst reliably elicited
at a dose of 60 mg/kg in C57BL/6J mice (Figure 1B). A dose of
80 mg/kg elicited generalized tonic-clonic seizures in all mice and
with a more consistent and shorter latency than with the 60 mg/kg
dose (Figure 1B). A dose of 100 mg/kg also produced rapid-onset
tonic-clonic seizures in all mice but was associated with high mortal-
ity (Figure 1B and data not shown). Ordinal logistic regression anal-
ysis was used to explore the dose dependence of the PTZ-induced
convulsions. PTZ dose was signiﬁcantly associated with Racine scores
(Figure 1C). A dose of 80 mg/kg was selected for further experiments.
To obtain molecular evidence for PTZ-induced seizure activity in the
model, we measured expression of activity-regulated genes in the hip-
pocampus. Transcript levels of FBJ osteosarcoma oncogene (Fos), a
calcium-dependent marker of neuronal activity and activity regulated
cytoskeletal-associated protein (Arc), another immediate early gene
responsive to intense neuronal activity, were strongly increased in
the hippocampus 30 min, but not at 4 hr, after PTZ-induced seizures
(Figures 1D and 1E). These data are consistent with PTZ inducing
short-lasting seizure activity. There was no evidence of irreversible
neuronal injury in tissue sections from mice after PTZ, as assessed
by Fluoro-Jade B (FJB) and NeuN (RNA binding protein, fox-1 ho-
molog [C. elegans] 3) staining (data not shown).
Expression of miR-134 is known to increase in various in vitro and
in vivo seizure models.15,19–22 We therefore investigated whether
PTZ-induced convulsions alter miR-134 levels in mice. TaqMan
miRNA assays showed that levels of mature miR-134 were signiﬁ-
cantly increased in the hippocampus, but not in the cortex, 30 min
after PTZ-induced generalized tonic-clonic seizures in mice (Fig-
ure 1F and data not shown).
Silencing miR-134 Protects against PTZ-Induced Seizures in
Mice
We next explored the consequences of silencing miR-134 on PTZ-
induced seizures. For these studies, we performed i.c.v. injection of
antagomirs targeting miR-134 (Ant-134) in mice.19,22 Previous
work has established a dose of these antagomirs that reduces hippo-
campal miR-134 levels by over 90% by 24 hr after injection.19 Accord-
ingly, we tested PTZ responses 24 hr after injection of Ant-134 and
Figure 1. Increased miR-134 Levels in Human TLE Hippocampus and after
PTZ-Induced Seizures in Mice
(A) Graph shows higher levels of mature miR-134 in TLE specimens compared to
autopsy control samples (n = 12/group; p = 0.037). (B) Graph shows the seizure
onset after challenge with different doses of PTZ (n = 3–8/group; p = 0.0061). Dotted
box inset shows individual data for seizure onset in mice treated with 80mg/kg PTZ.
(C) Racine scale readings for the lowest, intermediate, and highest doses (60, 80,
and 100 mg/kg) of PTZ (n = 3–8/group; p = 0.014, adjusted for clustering within
animal). (D and E) Graphs show mRNA levels of the molecular markers of hyper-
excitability c-Fos (D) and Arc (E) 30 min and 4 hr after PTZ injection (n = 3–5/group;
p = 0.0373 and p = 0.0125 for c-Fos and Arc, respectively). (F) Increased miR-134
expression in mouse hippocampus 30 min after PTZ injection in comparison with
vehicle control (saline) (n = 3–5/ group; p = 0.0266). All error bars shown asmeans ±
SEM. Veh, vehicle. *p < 0.05.
www.moleculartherapy.orgcompared them to responses in mice that received a scrambled anta-
gomir (Scr).
In Scr mice, delay to onset of ﬁrst tonic-clonic seizure after PTZ in-
jection was similar to that observed before in control mice (Figure 2A,
and compare to Figure 1B). Thus, the control antagomir did not alter
the normal response to PTZ in the model. The time to ﬁrst PTZ-
induced tonic-clonic seizure was signiﬁcantly longer in mice injected
with Ant-134 compared to Scr-injected animals (Figure 2A). The
severity of Racine-scored PTZ-induced seizures was also signiﬁcantly
lower in Ant-134- compared to Scr-injected mice (Figures 2B and
2C). Analysis of electrographically recorded seizure activity deter-
mined that electroencephalography (EEG) total power was lower in
Ant-134 mice compared to the control group after PTZ (Figure 2D).
Representative EEG recordings and frequency-amplitude heatmaps
are presented in Figure 2E.
Antagomir Silencing and Suppression of Activity-Regulated
Genes
We next analyzed brain tissue samples from Scr- and Ant-134-in-
jected mice for evidence of miRNA silencing and differences in
expression of activity-regulated genes. Analysis of the hippocampus
obtained after PTZ-induced seizures conﬁrmed that miR-134 expres-
sion was lower in Ant-134 pre-treated mice compared to Scr-treated
animals (Figure 3A). Ant-134 had no effect on levels of an unrelated
miRNA (Figure 3B).
Next, we assessed expression ofArc and c-Fos as molecular markers of
recent neuronal activity to support the clinically scored behavior and
EEG differences in Ant-134 mice. Quantitative real-time PCR anal-
ysis revealed increased c-Fos expression in the hippocampus of Scr-
injected mice after PTZ-induced seizures (Figure 3C). In contrast,
c-Fos levels were lower in Ant-134-injected mice, consistent with
reduced seizure severity (Figure 3C). This difference was also
apparent in the neocortex from the same animals (Figure 3C). Expres-
sion of Arc was increased in the hippocampus of Scr-injected mice
that received PTZ. Arc levels were not signiﬁcantly different in
Ant-134 mice compared to Scr-injected animals in the hippocampus
and neocortex after PTZ-induced seizures (Figure 3D).
Silencing miR-134 Does Not Alter Acute PPS-Induced Status
Epilepticus but Reduces the Later Occurrence of Spontaneous
Seizures in the Model
We turned next to the PPS model in rats, ﬁrst investigating effects on
miR-134 levels. TaqMan miRNA assays showed that levels of mature
miR-134 were not signiﬁcantly modiﬁed in the hippocampus of rats
at two different time points (Figure 4A). Next, we assessed the effect
of silencing miR-134 before stimulation on seizure severity during
status epilepticus. Rats were pre-treated with Ant-134 or Scr (i.c.v.)
24 hr before the 8-hr stimulation protocol. Analysis of electrograph-
ically recorded seizure activity determined that Scr-injected rats
presented a mean (± SEM) increase of 1,304.3% ± 94.9% in EEG total
power relative to baseline. This was similar to animals that were stim-
ulated but not receiving the oligonucleotide (data not shown). In ratsMolecular Therapy: Nucleic Acids Vol. 6 March 2017 47
Figure 2. Silencing miR-134 Protects against PTZ-Induced Seizures in Mice
(A) Latency to the first PTZ-induced tonic-clonic seizure for mice pre-treated with Scramble (Scr) or Ant-134 (n = 3–5/group; p = 0.0079). (B and C) Ant-134 mice display
milder convulsive behavior when compared to Scr-injected mice, presented as Racine scores (B; n = 3–5/group; p = 0.01) and duration of generalized tonic-clonic seizures
(C; n = 3–5/group; p = 0.01). (D) Graph shows EEG total power, depicting percentage increase from each animal’s own baseline data (n = 3–5/group; p = 0.0004). (E)
Representative heatmap showing frequency (in hertz) and amplitude (in microvolts) of EEG recordings over time (in minutes) for Scr-injected (left) and Ant-134-injected (right)
mice, followed by the respective EEG traces immediately below. All error bars shown as means ± SEM except in (A), which depicts medians and interquartile ranges.
**p < 0.01; ***p < 0.001.
Molecular Therapy: Nucleic Acidspre-treated with Ant-134, the severity of evoked seizures in the PPS
model was similar: EEG total power during seizures was a mean (±
S.E.M) of 1,244.6% ± 82.7% (percent of baseline).
Despite not seeing an acute anticonvulsant effect of Ant-134 in the
PPS model, we were nevertheless interested in whether silencing
miR-134 after status epilepticus in the model would alter the emer-
gence of recurrent spontaneous seizures. A key prior ﬁnding was
that silencingmiR-134 after status epilepticus induced by intra-amyg-
dala KA reduced the subsequent occurrence of spontaneous recurrent
seizures by over 90%.19 For these studies, rats underwent 8-hr stimu-
lation of the perforant pathway to induce epilepsy and the i.c.v. injec-
tion of Ant-134 or Scr was given at the end of stimulation. Rats were
then monitored with video-EEG until a ﬁrst spontaneous seizure was
recorded, typically 10–25 days after PPS, and they were then followed
for a further 8 weeks (Figure 4B).48 Molecular Therapy: Nucleic Acids Vol. 6 March 2017Epilepsy developed in all Scr-injected rats over the expected course,
with the ﬁrst spontaneous seizures appearing 1–4 weeks after status
epilepticus (Figures 4B and 4C). Scr-injected rats averaged 20
spontaneous seizures recorded during the 8-week recording time
(Figures 4D and 4E). In contrast, no spontaneous seizures were de-
tected over the 8-week period in six of seven rats injected with Ant-
134 after status epilepticus (Figures 4D–4F). Epilepsy emerged in
only a single rat treated with Ant-134 (Figures 4D and 4F). The
Fisher exact test determined that there was a signiﬁcant difference
in epilepsy development between the groups (p = 0.005). In terms
of effect size, Ant-134 prevented 86% of the risk of epilepsy, with a
95% conﬁdence interval (CI) of 12%–98%. An analysis of the dura-
tion of spontaneous seizures (electrographically deﬁned) revealed
that when spontaneous seizures occurred, they were similar be-
tween groups. That is, the average duration of a spontaneous
seizure in Scr-treated rats was 53.7 ± 14.4 s (n = 20 seizures,
Figure 3. Effects of Ant-134 on Molecular Markers of Seizures after PTZ
(A) Real-time qPCR analysis showing levels of miR-134 after PTZ-induced sei-
zures. Pre-treatment with Ant-134 effectively silenced miR-134 after PTZ-induced
seizures (p = 0.05 and p = 0.01 for Scr and Ant-134, respectively, compared to
vehicle [Veh]; p = 0.001 for Ant-134 versus Scr). (B) Expression of an unrelated
miRNA, miR-19a, was not affected by Ant-134 (p = 0.8238). (C and D) Graphs
present mRNA levels of c-Fos and Arc assessed 30 min after PTZ challenge in
hippocampus and cortex of Scr- and Ant-134-injected mice. Data were normal-
ized to RNU19 and b-actin for miRNA and mRNA expression, respectively. For c-
Fos, p = 0.0004 (hippocampus) and p = 0.0017 (cortex) for Scr compared to Veh,
and p = 0.01 (hippocampus) and p = 0.05 (cortex) for Ant compared to Scr. For
Arc, p = 0.032 (hippocampus) when comparing Scr to the vehicle group and
p = 0.152 (cortex) (n = 3–5/group). *p < 0.05 (compared to vehicle); **p < 0.01
(compared to vehicle); #p < 0.05 (compared to Scr). All error bars shown as
means ± SEM.
www.moleculartherapy.orgfrom ﬁve rats), which was similar to the duration in epileptic rats in
the PPS model that did not receive an i.c.v. injection (49.4 ± 15.9,
n = 20 seizures). In the Ant-134 rat that developed epilepsy, the
average duration of a spontaneous seizure was 52.3 ± 16.2 s
(from n = 12 seizures).Ant-134 Increases the Delay to Seizure Onset in Ex Vivo Brain
Slices Exposed to High K+
Having observed a disparity between the acute anti-seizure effects of
Ant-134 pre-treatment in the PTZ and PPS models, we sought to
examine the effect of Ant-134 on naive, non-epileptic tissue and
whether the effects were due to long range networks or if local cir-
cuitry was sufﬁcient to mediate any seizure protection. We injected
Ant-134 in vivo in rats and subsequently prepared ex vivo brain sli-
ces (Figure 5A). These slices were then exposed to a 9-mM K+
seizure challenge,30 to determine whether Ant-134 protects against
epilepsy in local circuits of the isolated slice in the absence of
epileptogenesis.
Onset of activity was delayed in Ant-134-treated slices by 176 s rela-
tive to the control (Figures 5B and 5C). This effect was statistically sig-
niﬁcant (Mann-Whitney U test, p = 0.002, a = 0.025, power = 0.87).
We also compared the power of epileptiform activity and duration of
seizure-like events in these data; these effects were not statistically sig-
niﬁcant (power: t test, p = 0.70; duration: Mann-Whitney U test, p =
0.067). This ﬁnding suggests that Ant-134 can confer seizure resis-
tance in naive tissue and thus mediate its effect even in the absence
of epileptogenesis. In addition, preservation of the seizure resistance
in isolated slices indicates that at least some of the effects of Ant-
134 are due to local changes in activity.
DISCUSSION
The present study provides important additional evidence of the anti-
convulsant and disease-modifying effects of LNA-based antagomirs
targeting miR-134 in animal models of epilepsy. Our study shows
that Ant-134 is an anticonvulsant in an acute chemoconvulsant
model (PTZ in mice) and Ant-134 had anti-epileptogenic activity
in the perforant pathway stimulation model of epilepsy in rats.
Ant-134 also confers resistance to epileptic activity in naive tissue, re-
ﬂected as a delay to activity onset following a seizure challenge in
ex vivo brain slices. We also report that miR-134 levels are elevated
in the hippocampus of patients with pharmacoresistant TLE. The
therapeutic potential of targeting miR-134 in established epilepsy
will require additional studies, but our ﬁndings may encourage
further research or pre-clinical development of this miRNA-based
treatment for epilepsy.
Despite the recent introduction of two additional AEDs (perampanel
and brivaracetam), new drug development in epilepsy faces signiﬁ-
cant challenges.1,2,32 New targets are required that can treat pharma-
coresistant patients or have disease-modifying effects that are not
served by current therapies. miRNAs have emerged as potential tar-
gets of the future via their inﬂuence on neuronal microstructure, glio-
sis, neuroinﬂammation, and ion channels.8,33 Silencing miR-134 has
produced the most convincing anti-seizure effects to date, reducing
status epilepticus in pre-treatment paradigms in the intra-amygdala
KA and pilocarpine models and exerting potent long-term effects
on spontaneous seizure development.19,22 This miRNA is also an
attractive target, since studies show increased levels of miR-134
within the temporal lobe of adult and pediatric patients withMolecular Therapy: Nucleic Acids Vol. 6 March 2017 49
Figure 4. Ant-134 Reduces Spontaneous Seizures after PPS-Induced
Status Epilepticus in Rats
(A) miR-134 levels in rat hippocampus at “early” and “late” time points after PPS in
comparisonwith the respective non-stimulated controls (p = 0.3309, n = 3–4/group).
(B) Schematic illustrates PPS experimental design. (C) Representative EEG trace of a
spontaneous seizure captured in a Scr-injected rat. (D–F) Individual rat (i–vi/vii)
weekly seizure counts schematic (D) and graph (F) showing spontaneous seizures
during long-term monitoring (8 weeks after the first spontaneous seizure). (E)
Spontaneous seizure counts were summed by group. **p < 0.01 (for n = 6–7/group).
All error bars shown as means ± SEM. ns, non-significant; SE, status epilepticus.
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50 Molecular Therapy: Nucleic Acids Vol. 6 March 2017intractable epilepsy.19,20 We report here that miR-134 is also elevated
in the hippocampus of adults with pharmacoresistant TLE, although
there are potential confounders with comparing resected material
from patients to autopsy control samples.34 The present study has
answered key questions that could facilitate pre-clinical development
by showing that Ant-134 has anticonvulsant effects in non-status epi-
lepticus models and is disease modifying in another species. The ﬁrst
important ﬁnding was that pre-treatment with Ant-134 strongly sup-
pressed seizures in the mouse PTZ model. Effects on both clinical
behavior, including delaying the time to ﬁrst convulsive seizure,
and electrographic seizure activity were seen. Thus, lowering brain
levels of miR-134 can exert anti-excitability effects, and this implies
that miR-134 has a role in setting excitability thresholds in the brain.
This is thought to be due to regulation of proteins that control den-
dritic morphology,14,15 although other targets are known.35 Ant-134
did not fully prevent seizures in the PTZ model; rather, it delayed
and minimized their severity, a ﬁnding most closely matching the ef-
fect of Ant-134 in the pilocarpine model of status epilepticus.22 It may
not be possible to fully prevent all seizures using Ant-134 in chemo-
convulsant models, but further adjustments to antagomir dose or
delivery may yield optimal seizure-suppressive effects. PTZ triggers
seizures via GABAergic blockade; this differs from the mechanism
by which status epilepticus is induced by KA and pilocarpine, which
work by promoting glutamatergic and cholinergic transmission,
respectively. This suggests that Ant-134 may be effective for epilepsies
of various etiologies, which, in patients, can vary considerably
between trauma, stroke, infection, genetic, and other causes.36 This
could maximize the potential patient population that could beneﬁt
from Ant-134. Our studies also show that PTZ-induced convulsions
increase brain levels of miR-134, transcription of which is probably
mediated by myocyte enhancer factor 2C.15 We did not observe an
increase in miR-134 after perforant pathway stimulation in the rat.
This was surprising, although changes to miR-134 levels are not al-
ways detected after chemoconvulsive stimuli,37 and we cannot rule
out a technical explanation (e.g., the time points selected or a sub-
ﬁeld-speciﬁc effect that was masked by the use of the whole
hippocampus).
Our study included an analysis of the short-term effects of Ant-134 on
neuronal activity-regulated genes in the PTZ model. Expression of
genes such as c-Fos and Arc is a well-established surrogate marker
of recent seizure activity, the protein products of which are involved
in coordinating synaptic plasticity and adaptation to excessive
neuronal stimulation.38,39 Unexpectedly, only levels of c-Fos, and
not Arc, showed the expected reductions in Ant-134 mice after PTZ
seizures. The explanation for this difference between markers is un-
certain. It is known that c-Fos induction is calcium dependent,
whereas Arc expression can be induced via calcium-independent
pathways.38,39 Therefore, Ant-134 treatment may have reduced
seizure severity sufﬁcient to prevent c-Fos induction, such as by mini-
mizingN-methyl-D-aspartate (NMDA) receptor opening, but enough
residual neuronal excitation remained to upregulate Arc. These ﬁnd-
ings provide additional evidence of the scale and nature of seizure
suppression by Ant-134 and suggest molecular markers that can
Figure 5. Ant-134 Delays Epileptiform Activity Onset in Ex Vivo Slices in
Response to 9 mM K+
(A) Schematic of experimental design. Rats were injected with Ant-134 or control 2–
4 days prior to ex vivo slice preparation. Local field potential recordings were made
in hippocampal CA1. (B) Bar chart shows that epileptiform activity onset was de-
layed by Ant-134 (**p = 0.002, a = 0.025; statistical power = 0.87, Mann-Whitney U
test; control, n = 9 slices from 3 rats; Ant-134, n = 11 slices from 3 rats). (C)
Representative traces of epileptiform activity elicited by 9 mM K+ in slices from
control or Ant-134-treated rats. All error bars shown as means ± SEM.
www.moleculartherapy.orgdistinguish effects of miRNAmanipulations on different components
of seizure responses.
In the present study, we observed that pre-treatment of rats with
Ant-134 did not protect against perforant pathway stimulation-
induced status epilepticus. This suggests its potential limitations as
an acute anticonvulsant. While there are examples of anticonvulsants
producing effects in some but not all models, these ﬁndings suggest
that Ant-134 may have the most clinical value as an anti-epileptogenic
treatment. Previous work showed that injection of Ant-134 after status
epilepticus in mice suppressed the later occurrence of spontaneous
seizures by 90%, evidence of a disease-modifying effect in the intra-
amygdala KA model.19 Here, we found nearly identical anti-epilepto-
genic effects of Ant-134 in a different model in rats. This is the only
demonstration, to our knowledge, of any disease-modifying treatment
in the PPSmodel in rats. The PPS technique induces hippocampal scle-
rosis and recurrent spontaneous seizures,29,40 and it provides a means
to trigger epilepsywithout thebias or other issues41 associatedwith che-
moconvulsants. Ant-134 was injected shortly after triggering status ep-
ilepticus in order to model a reasonably realistic clinical scenario, such
as a patient being treated shortly after an initial precipitating injury.
Ant-134 had dramatic and potent effects, with the majority of Ant-
134 rats (six of seven, 86%) never developing spontaneous recurrent
seizures. Notably, spontaneous seizures in the study with the intra-
amygdala KAmodel did occur in all Ant-134mice, albeit with dramat-
ically lower seizure frequency.19 This differencemay relate to the extent
of hippocampal injury or another aspect of the epileptic phenotype,such as the frequency of spontaneous seizures. Thus, presently we see
a possible additional therapeutic action of Ant-134, whereby post-
treatment is capable of fully preventing epilepsy at least in some
models. We cannot, of course, exclude that epilepsy might have devel-
oped in some of the Ant-134 rats at some point in the future. However,
we recorded for 8 weeks beyond the standard latent period.We further
corroborated the anti-seizure effect of Ant-134 by using an acute
seizure challenge with high potassium in otherwise healthy (ex vivo)
tissue. Inhibitory neurotransmission is retained in this model (in
contrast to PTZ) and there is no hippocampal sclerosis (unlike PPS),
further suggesting thatAnt-134 can be therapeutic inmultiple epileptic
syndromes with varyingmechanisms.We observed a delay in the onset
of epileptiform bursts in brain slices that had been pre-treated with
Ant-134. This ﬁnding suggests that epileptogenesis is not required
for Ant-134 to mediate its effects on seizure onset. We did not see
any signiﬁcant changes in the power or duration of epileptiform activ-
ity; however, these parameters are highly variable in brain slices, which
can obscure potential effects. In addition, we propose that Ant-134 can
mediate seizure protection in the hippocampus via effects on local cir-
cuitry, because long range connections would likely be severed during
the slicing process. The anti-epileptogenic actions of Ant-134 may be
independent of the etiology of the initial precipitating injury, although
this will require further testing (e.g., in models of trauma or infection-
induced epilepsy). In addition, upregulation ofmiR-134 is not essential
for Ant-134 to produce anti-epileptogenic effects, since miR-134 levels
were not altered after PPS-induced status epilepticus. Thus, epilepsy
can be dramatically suppressed in two different in vivo models, and
one in vitro, in two different species. This provides strong support
for and is an argument for further development of Ant-134 for epilepsy
treatment or prevention.
The safety of targeting miR-134 using antagomirs has not yet been
explored in depth. Antagomirs targeting a liver-expressed miRNA
have been given to humans and were found to be well tolerated and
effective against hepatitis C in clinical trials.42 There are concerns,
obviously, that because Ant-134 can alter dendritic spines, it could
have effects on cognition.17 Studies to date have not identiﬁed such
problems, with natural exploratory behavior and performance in a
hippocampus-dependent task found to be normal in mice a few
days after i.c.v. injection of Ant-134.19,22 However, more demanding
tests of cognition or learning will need to be performed. Another
factor that argues for general safety is that mice and rats have been
recorded for at least 2 months after brain injections of Ant-134.
Nevertheless, pre-clinical development will necessitate an extensive
battery of toxicity and safety testing.
Work to date on Ant-134 satisﬁes certain recommendations for
testing and evaluating novel therapies for epilepsy, with seizure-sup-
pressive effects demonstrated in ﬁve different models and two
different species.1,2,43,44 There are, however, additional seizure models
that could be used during any future pre-clinical development. This
includes kindling, a popular model that has been successful in iden-
tifying AEDs with novel mechanisms of action.45 Ant-134 has not
been tested in female rodents.While this is not an essential step beforeMolecular Therapy: Nucleic Acids Vol. 6 March 2017 51
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sponses may be worth investigating in future studies and sexual
dimorphism in miRNA expression has been reported, although not
for miR-134.46,47
It will also be of value to understand how Ant-134 produces its potent
seizure-suppressive effects. The most likely mechanism is upregula-
tion of one or more proteins due to de-repression of a miR-134 target.
Previous work has shown that miR-134 is uploaded into the RNA-
induced silencing complex after seizures, which facilitates targeting
of mRNAs, and in vitro studies suggest that the neuroprotective
effects of Ant-134 are due to de-repression of LIM domain kinase
1.19 Ant-134 treatment also increases dendritic spine volume and
changes spine number in the hippocampus,19,22 which could inﬂuence
excitability and would also be consistent with a mechanism involving
protection ofmiR-134 targets such as LIMdomain kinase 1 or pumilio
RNA-binding family member 2.15 Altered spine volume and number
is consistent with our observation of a robust local effect of suppress-
ing miR-134 on delaying epileptiform activity, although additional ef-
fects on long range connections cannot be ruled out. We must also
consider that the acute seizure-suppressive effects and long-term
anti-epileptogenesis effects may arise from different mechanisms.
Ultimately, in vivo studies will be necessary to determine the anti-
seizure mechanism of Ant-134 (e.g., by analyzing gene expression net-
works, quantifying the proteome, and applying techniques to validate
antagomir-miRNA targeting such as polysome shift assays).48
What are the next steps for translation or pre-clinical development?
An obvious question is whether and how antagomirs could be given
to patients. Their large size precludes their passing an intact blood-
brain barrier (BBB).49 Recent work has explored methods to
circumvent the BBB, including conjugating antagomirs with brain-
penetrating peptides50 or administering antagomirs via intranasal
injection.19,51 The BBBmay also be open after certain epilepsy-precip-
itating injuries52 or it can be physically breached, such as through use
of ultrasound.53 Another question is whether Ant-134 injection into
already epileptic animals could alter the frequency or duration of
spontaneous seizures or attendant hippocampal pathology. Success
with that approach could provide novel treatment opportunities for
the population of drug-resistant patients for whom surgery or other
alternatives to AEDs are either not possible or not effective currently.
In summary, the present study provides important additional valida-
tion of the potent seizure-suppressive and possibly disease-modifying
effects of Ant-134 in two different animal models and one brain slice
model. The effectiveness of Ant-134 and the potency of seizure sup-
pression suggest a target for drug development in epilepsy that could
provide additional effects beyond those provided by any currently
marketed drug for epilepsy.
MATERIALS AND METHODS
Human Brain Tissue Samples
This study was approved by the Ethics (Medical Research) Commit-
tee of Beaumont Hospital of Dublin (no. 05/18) and written informed52 Molecular Therapy: Nucleic Acids Vol. 6 March 2017consent was obtained from all patients. The control (autopsy) hippo-
campus (n = 12) was obtained from 12 individuals. Autopsy control
tissue was obtained from the University of Maryland Brain and Tissue
Bank. Fresh frozen specimens were from individuals without known
neurological disease (Table S1). Patients (n = 12) were referred for
surgical resection of the temporal lobe by an epileptologist (N.D.)
following neurological assessment, video-EEG recording, and MRI/
neuroimaging. Each patient was determined to have medically intrac-
table TLE with a history of recurring seizures (Table S2). All patients
were taking anticonvulsant medication prior to surgery. Patients un-
derwent left or right temporal lobe resection. The hippocampus was
obtained and a portion of each specimen was frozen in liquid nitrogen
and stored at 70C until use. A pathologist (M.A.F.) assessed
the hippocampus as part of the pathologic evaluation, addressed
the degree of hippocampal sclerosis, and described other pathologic
changes.
Animals
All animal experiments were performed in accordance with the Euro-
pean Communities Council Directive (2010/63/EU). Procedures in
mice were approved by the Research Ethics Committee of the Royal
College of Surgeons in Ireland (REC-842), under license from the
Ireland Health Products Regulatory Authority (AE19127/001). Pro-
cedures in rats were performed under authorization of the Philipps
University Bioethics Committee and were approved by the local
regulation authority (Regierungspräsidium Gieben), or they were
performed according to the UK Animals (Scientiﬁc Procedures)
1986 Act (PPL 70-7684) and approved by local ethical review (Uni-
versity College London). Male adult C57BL/6J mice (20–25 g) and
male Sprague-Dawley rats (325–350 g or 200–300 g; all from Harlan)
were used in all studies. Animals were housed in on-site barrier-
controlled facilities having a 12-hr/12-hr light/dark cycle with ad libi-
tum access to food and water.
PTZ Model of Generalized Tonic-Clonic Seizures in Mice
Mice were equipped for EEG recordings under surgical anesthesia
(isoﬂurane; 5% induction, 1%–2% maintenance) in a mouse-adapted
stereotaxic frame. Body temperature was maintained within the
normal physiological range with a feedback-controlled heat pad (Har-
vard Apparatus). After a midline scalp incision, partial craniectomies
were performed and animals had skull-mounted recording electrodes
placed and ﬁxed with dental cement. A second cohort of mice had
EEG electrodes and a guide cannula implanted to allow i.c.v. injec-
tions.19 This cannula was placed on the dura mater with the following
coordinates from the bregma: anterior-posterior (AP), +0.3 mm;
lateral (L), +0.9 mm; and ventral (V), 2.0 mm. After recovery
from surgery, mice were connected to the lead socket of a swivel
commutator, which was connected to a Grass TwiN digital EEG sys-
tem. Baseline recordings were obtained, after which mice were in-
jected (intraperitoneally [i.p.]) with different doses of PTZ (60, 80,
or 100 mg/kg). Lorazepam (8 mg/kg, i.p.) was administered after
the ﬁrst tonic-clonic seizure to reduce morbidity and mortality.
Mice were followed for 30 min or 4 hr after PTZ administration for
the appearance of seizures by electrographic and behavioral methods.
www.moleculartherapy.orgAfter the observation period, mice were deeply anesthetized (pento-
barbital) and transcardially perfused, and their brains were removed
for analysis of gene expression or histological assessment. The second
cohort of mice received i.c.v. injection of 0.12 nmol/2 mL 30-choles-
terol-tagged locked nucleic acid oligonucleotide targeting miR-134
(Ant-134) or its respective control, a non-targeting scrambled version
of the antagomir (Scr; 0.12 nmol/2 mL) (Exiqon A/S), as previously
described.19,22 Twenty-four hours later, mice were connected to an
EEG system and a baseline recording was obtained. Next, mice
were injected with PTZ (80 mg/kg, i.p.). Lorazepam (8 mg/kg, i.p.)
was administered after the ﬁrst tonic-clonic seizure to reduce
morbidity and mortality. These mice were followed up for 30 min af-
ter PTZ administration for the appearance of seizures. After this
period, mice were deeply anesthetized (pentobarbital overdose) and
transcardially perfused (PBS) for further assessments.
Perforant Pathway Stimulation Model of Epilepsy in Rats
Under isoﬂurane (5% induction,3%maintenance) anesthesia, bipo-
lar stainless-steel stimulating electrodes (NEX-200; Rhodes Medical
Instruments) were positioned in the angular bundles of the perforant
pathway and custom unipolar recording electrodes (crafted from
796000; A-M Systems) were lowered into the dorsal dentate gyrus.
Electrode locations were determined by optimizing the potentials
evoked by low-frequency PPS. Electrodes and ground screws were
connected to miniature wireless transmitters (FT20; Data Sciences In-
ternational) that were implanted subcutaneously on the animal’s
ﬂank. Dental cement connected the electrodes to anchor screws and
the skull. Plastic connectors (GS09PLG; Ginder Scientiﬁc) joined
the electrodes with stimulation/recording equipment. The PPS proto-
col utilized a paradigm designed to evoke and maintain hippocampal
seizure activity throughout the stimulation, but not convulsive status
epilepticus,29 which consisted of continuous, bilateral 2-Hz paired-
pulse stimuli, with a 40-ms interpulse interval, plus a 10-s train of
20 Hz single-pulse stimuli delivered once per minute, generated by
an S88 stimulator (Grass Instruments). All pulses (0.1-ms duration)
were delivered at 20–24 V, as this voltage reliably evokes granule
cell discharging without tissue-damaging hydrolysis.29,40 The current
associated with these voltages was typically between 15 and 30 mA.
Stimulation evoked population spikes with amplitude of 5–10 mV.
No samples displayed any signs of hydrolysis (e.g., holes around the
stimulating electrodes). As described previously, stimulation for
30 min (on 2 consecutive days) required only isoﬂurane to terminate
seizures.29 Eight-hour stimulation on the third day did not induce
convulsive status epilepticus and, therefore, did not require pharma-
cological termination. All animals survived the 8-hr stimulation. Rats
were randomly divided in three cohorts to assess the following: (1)
miR-134 expression after PPS (24 hr, 4 days, and 14 days); (2) the ef-
fect of Ant-134 on PPS-induced status epilepticus, in which rats were
pre-treated with Ant-134 or Scr (0.36 nmol/6 mL, i.c.v.; Exiqon A/S)
24 hr before the 8-hr stimulation; and (3) the effect of Ant-134 on ep-
ileptogenesis, in which rats were injected with 0.36 nmol/6 mL (i.c.v.)
of Ant-134 or Scr (Exiqon A/S) immediately after 8-hr stimulation.
Five rats were excluded from this study due to practical issues (e.g.,
blocked cannula). For statistical purposes, we pooled samples from24 hr and 4 days after PPS as an “early” time point, while 14-day
samples were considered as the “late” time point.
Behavioral and EEG Analysis
Mouse EEG data were analyzed and quantiﬁed using LabChart 8
software (AD Instruments). PTZ-induced seizures were deﬁned as
high-amplitude (>2 baseline) high-frequency (>5 Hz) polyspike
discharges lasting >5 s. For statistical purposes, we assigned a cut-
off time of 1,800 s for those animals that did not present seizures dur-
ing the observation period. From the EEG recordings, we calculated
the delay to ﬁrst seizure, the total power, and the percentage of total
power/spectral bands, as previously described.19,54 EEG total power
was plotted as the percentage of baseline recording (each animal’s
EEG power post-seizure compared to its own baseline EEG). Clinical
behavior was scored using the following adapted Racine scale: score
0, no seizures observed; score 1, rhythmic mouth and facial move-
ment; score 2, rhythmic head nodding (bobbing); score 3, forelimb
clonus; score 4, rearing and bilateral forelimb clonus; and score 5,
rearing and falling (stay fallen on rear side; tonic-clonic seizures).
Behavior was scored by an observer blind to treatment. The highest
score reached during every 5 min during the 30 min after PTZ was
recorded.
For studies in rats, EEG activity during and after PPS was ampliﬁed
and recorded digitally at 2 kHz utilizing a PowerLab 16/35 and Lab-
Chart software versions 7 and 8 (AD Instruments). Spontaneous
granule cell layer activity was recorded continuously (24 hr/day)
and stored digitally and automatically in 3-hr epochs. Each day, we
analyzed the preceding 24 hr of recordings, as well as all events
with amplitudes exceeding 120% of average baseline. Potential
seizures were related to behavior on the time-stamped video record-
ings. Continuous (24 hour/7 day) video monitoring utilized
Edimax 7010W infrared cameras. Video ﬁles were captured at
12–15 frames/sec and were time-stamped for integration with the
electrophysiological data using SecuritySpy surveillance software
(Ben Software) and stored digitally. Conﬁrmed seizures were scored
according to the Racine scale.
Epileptiform Activity Induced by 9 mM K+ in Ex Vivo Rat Brain
Slices
Rats were anesthetized with isoﬂurane (5% induction,2% mainte-
nance as appropriate) and mounted in a stereotaxic frame. We in-
jected Ant-134 (0.12 nmol) in 1 mL TE buffer (Life Technologies) at
coordinates relative to the bregma: AP, 0.92 mm; medial-lateral
(ML), +1.3 mm, and dorsal-ventral (DV), 3.3 mm to target the
lateral ventricle. To allow the rats to fully recover from the analgesic
drugs and to coincide with the maximal anti-epileptic effect seen
in vivo, slices were prepared 2–4 days following stereotaxic surgery.19
Rats were anesthetized brieﬂy with inhalational isoﬂurane and heavily
with i.p. sodium pentobarbital and transcardially perfused with ice-
cold sucrose artiﬁcial cerebrospinal ﬂuid (aCSF; in mM: 205 sucrose,
10 glucose, 2.5 KCl, 0.1 CaCl2, 5 MgCl2, 26 NaHCO3, and 1.2 NaH2
PO4.H2O; osmolarity, 295 mOsm). The brain was quickly dissected
into ice-cold sucrose aCSF and transferred to a Campden 700 SMZMolecular Therapy: Nucleic Acids Vol. 6 March 2017 53
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horizontal orientation between the bregma at approximately 7.1
and – 5.1 mm. For storage, slices were submerged in oxygenated
normal aCSF (in mM: 125 NaCl, 10 glucose, 3 KCl, 1 MgCl2, 2
CaCl2, 26 NaHCO3, and 1.25 NaH2PO4.H2O; osmolarity, 290
mOsm) and allowed to recover at room temperature for at least
60 min prior to recordings.
Slice recordings were made using a membrane chamber (Scientiﬁc
Systems Design), a modiﬁed submerged chamber,55 which improves
oxygen supply to the tissue and supports greater epileptiform bursts
than conventional submerged recording chambers. Slices were
continually perfused with aCSF, heated to 32C, at a ﬂow rate of
16 mL/min. For local ﬁeld potential (LFP) recordings, borosilicate
glass recording micropipettes (resistance, 3–4 MU) were placed into
hippocampal CA1b stratum pyramidale and epileptiform activity
was induced by raising the perfusing KCl concentration to 9 mM.
Recordings were continued for 30 min.
Quantitative Real-Time PCR
Total RNAwas isolated from brain samples using Trizol (Invitrogen),
as described previously.19,54 For mRNA qPCR, 1 mg total RNA was
used to generate cDNA by reverse transcription using the SuperScript
III reverse transcriptase enzyme (Invitrogen). Standard PCR was
performed using 2 mL total cDNA. The PCR ampliﬁcation was per-
formed for 50 cycles on a Thermocycler (Applied Biosystems). Quan-
titative real-time PCR was performed using a LightCycler 1.5 (Roche
Diagnostics) in combination with QuantiTect SYBR Green PCR kit
(QIAGEN) as per the manufacturer’s protocol with 25 mM of primer
pairs used. Speciﬁc primers for each gene assayed were purchased
from Sigma and sequences used were as follows: actin, beta (Actb)
(forward [F], ggttggccttagggttcagg; reverse [R], gggtgtgatggtgggaatgg);
c-fos (F, cattcagaccacctcgacaa; R, ggaattaacctggtgctgga); and Arc (F,
agcagcagacctgacatcct; R, gtgatgccctttccagacat). Data were normalized
to Actb and relative mRNA transcript levels were quantiﬁed using the
DDCT method. For miRNA, 250 ng RNA was reverse transcribed
using stem-loop speciﬁc primers for mmu-miR-134 (Applied Bio-
systems) and real-time quantitative PCR was carried out on a
7900HT Fast Real-Time System (Applied Biosystems) using TaqMan
miRNA assays. Expression of RNU19 was used for normalization. A
relative fold change in expression of miR-134 was determined using
the DDCT method.19,56 Speciﬁc miRNA assays were obtained from
ThermoFisher Scientiﬁc for miR-134 (ID 001186), miR-19a (ID
000395), and RNU19 (ID 001003). Data were normalized to
RNU19 and relative miRNA expression levels were quantiﬁed using
the DDCT method.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism and Stata
Release 14 software, and a p value < 0.05 was considered signiﬁcant.
Latencies to tonic-clonic seizures were analyzed by the Kruskal-
Wallis test, followed by the nonparametric Dunn multiple compari-
son test when indicated. Data are presented as medians and
interquartile ranges. Racine scores were analyzed by ordinal logistic54 Molecular Therapy: Nucleic Acids Vol. 6 March 2017regression and adjusted for clustering within animal. Total time spent
in seizures, mean amplitude, frequency, total power of EEG
recordings, and mRNA levels were analyzed by the Student t test or
one-way ANOVA followed by the Bonferroni test, depending on
the experimental design. PPS model data were analyzed by the Fisher
exact test. Ex vivo brain slice data were analyzed using the Mann-
Whitney U test. Three comparisons were made from the same data
and a (signiﬁcance level) was consequently reduced to 0.025 for these
experiments. Data are expressed as means ± SEM.
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